Description: Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Home Page: www.shieldtherapeutics.com
STX Technical Analysis
Northern Design Centre
Gateshead,
NE8 3DF
United Kingdom
Phone:
44 1915 118 500
Officers
| Name | Title |
|---|---|
| Mr. Gregory P. Madison | CEO & Exec. Director |
| Dr. Christian Schweiger M.D., Ph.D. | Co-Founder & Non Exec. Director |
| Mr. Hans-Peter Rudolf | Chief Financial Officer |
| Ms. Lucy Huntington-Bailey | Gen. Counsel & Company Sec. |
| Ms. Suzanne Wood | Group HR Director |
| Ms. Carol Akinola | Head of Pharmacovigilance & Medical Information |
| Dr. José A. Menoyo M.D. | Chief Medical Officer |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 65.3595 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5334 |
| Price-to-Sales TTM: | 5.8707 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |